A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

465 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-18

Study Completion Date

2023-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is one randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with standard 1st-line chemotherapy in treatment-naïve advanced non-small cell lung cancer (NSCLC); and evaluate the population with the best predictive biomarkers, i.e., positive diagnosis population.

About 450 subjects with advanced non-small cell lung cancer without activated EGFR mutation (exon 19 deletion, or exon 21 L858R, exon 21 L861Q, exon 18 G719X or exon 20 S768I mutations) and ALK fusion will be 2:1 randomized into two groups, JS001 combined with the standard 1st-line chemotherapy will be given in the study group whereas placebo combined with standard 1st-line chemotherapy will be given in the control group. The stratification will be based on the following factors:

PD-L1 expression (TC≥1% vs TC\<1%); Smoking state (often smoking vs no smoking or infrequent smoking); Pathological type (squamous cell carcinoma vs non-squamous cell carcinoma).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

NCT04158440

Stage II-III Non-small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE3

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

NCT07039656

Stage IB-IIIB NSCLC Stage IIB-III NSCLC

RECRUITING PHASE2

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

NCT04012606

Small Cell Lung Cancer

COMPLETED PHASE3

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

NCT04606303

Locally Advanced NSCLC

UNKNOWN PHASE2

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

NCT05842018

Non Small Cell Lung Cancer Recurrent

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment-naive Advanced Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group TORIPALIMAB combined with standard chemotherapy

Group Type EXPERIMENTAL

TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

Intervention Type DRUG

TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.

Group Placebo combined with standard chemotherapy

Group Type PLACEBO_COMPARATOR

TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

Intervention Type DRUG

TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JS001, TAB001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Only the patients meeting all the following criteria can be eligible to participate in the trial:

1. Histologically and/or cytologically confirmed stage IV non-small cell lung cancer and ALK fusion
2. At least one measurable lesion 3 No history of any systemic anti-tumor therapy.

4\. Agreement on providing formalin fixed tumor tissue specimen or fresh biopsy tissue from tumor lesions after diagnosis of metastasis 6. Age of 18-75 years 7. ECOG Scores 0-1; 8. Expected survival ≥ 3 months;

Exclusion Criteria

1. Known allergy to recombinant humanized anti-PD-1 monoclonal antibody drug and its components;
2. Histologically or cytopathologically confirmed combination with small cell lung cancer component or sarcomatoid lesion;
3. Current participation in and receiving other study treatment, or participation in treatment of one study drug within 4 weeks prior to administration of JS001;
4. Previous use of systematic chemotherapy for advanced NSCLC; targeted therapy for advanced NSCLC
5. Previous use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cells synergetic stimulation or checkpoint pathway, such as IDO, IL-2R, GITR);
6. Chest (lung) radiotherapy \> 30 Gy within 6 months prior to the start of study treatment.
7. Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening;
8. Known active central nervous system (CNS) metastasis and/or cancerous meningitis;
9. Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression
10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage
11. Uncontrollable or symptomatic hypercalcemia
12. Clinically uncontrolled active infection, including but not limited to acute pneumonia;
13. Uncontrollable major epileptic seizure or superior vena cava syndrome
14. Previous or current combination with other malignancies ;
15. History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening;
16. Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease;
17. Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle;
18. Vaccination of live-virus vaccine within 30 days after the start of planned treatment

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No